Enteral nutrition in the management of Crohn's disease

Journal of Parenteral and Enteral Nutrition

Volumn 29, Issue 4_suppl, 2005, Pages S108-S117

  Griffiths, Anne M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AZATHIOPRINE; BIOLOGICAL PRODUCT; BUDESONIDE; CORTICOSTEROID; FATTY ACID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; OMEGA 6 FATTY ACID; PLACEBO; PREDNISONE; PROTEIN;

ARTICLE; BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DIET THERAPY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ENTERIC FEEDING; ENTERITIS; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATION; INTESTINE; INTESTINE MUCOSA; META ANALYSIS; NOSE FEEDING; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK FACTOR; TREATMENT OUTCOME; WOUND HEALING; ELEMENTAL DIET; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MICROBIOLOGY; PATHOLOGY; REVIEW; STANDARD;

CROHN DISEASE; ENTERAL NUTRITION; EVIDENCE-BASED MEDICINE; FOOD, FORMULATED; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTESTINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 27744523071     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/01486071050290S4S108     Document Type: Article

References (44)

1. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603.
2. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 537-539.
3. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kB. J Biol Chem. 2001; 276: 4812-4818.
4. Bonen DK, Cho J. The genetics of inflammatory bowel disease. Gastroenterology. 2003; 124: 521-536.
5. Shanahan F. Crohn's disease. Lancet. 2002; 359: 62-69.
6. Bouma G, Strober W. The immunologic and genetic basis of inflammatory bowel disease. Nature Rev. 2003; 3: 521-555.
7. Cominelli F. Cytokine-based therapies for Crohn's disease -new paradigms. N Engl J Med. 2004; 351: 2045-2048.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
9. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
10. Panaccione R, Fedorak RN, Aumais G, et al. Canadian Association of Gastroenterology Practice Guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol. 2004; 18: 503-508.
11. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999; 116: 1029-1034.
12. Voikt AJ, Echave V, Feller JH, Brown RA, Gurd FN. Experience with elemental diet in the treat of inflammatory bowel disease. Is this primary therapy? Arch Surg. 1973; 107: 329-335.
13. Gassull MA, Stange EF. Nutrition and diet in inflammatory bowel disease. In: Satsangi J, Sutherland LR, eds. Inflammatory Bowel Diseases. London, United Kingdom: Elsevier, 2003: 461-474.
14. Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with inflammatory bowel disease. J Pediatr Gastro Nutr. 2004; 39: 15-27.
15. McHugh K, Castonguay TW, Collins SM, Weingarten HP. Characterization of suppression of food intake following acute colonic inflammation in the rat. Am J Physiol. 1993; 265: R1001-R1005.
16. Azcue M, Rashid M, Griffiths A, Pencharz P. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and prednisone treatment. Gut. 1997; 41: 203-207.
17. Ballinger AB, Azooz O, El-Haj T, et al. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 2000; 46: 1-6.
18. DeBenedetti F, Alonzi T, Moretta A, et al. Interleukin-6 causes growth impairment in transgenic mice through a decrease in insulin-growth factor I. J Clin Invest. 1997; 99: 643-650.
19. Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988; 94: 603-610.
20. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut. 1996; 38: 543-548.
21. Fernandez-Banares F, Cabre E, Gonzalez-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn's disease. Gut. 1994; 35: S55-S59.
22. Griffiths AM, Ohlsson A, Sherman P, Sutherland LR. Meta-analysis of enteral nutrition as primary treatment of active Crohn's disease. Gastroenterology. 1995; 108: 1056-1067.
23. Fernandez-Banares F, Cabre E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr. 1995; 19: 356-364.
24. Teahon K, Smethurst P, Pearson M, et al. The effect of elemental diet on permeability and inflammation in Crohn's disease. Gastroenterology. 1991; 101: 84-87.
25. Sanderson IR, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut. 1987; 28: 1073-1076.
26. Breese EJ, Michie CA, Nicholls SW, et al. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease. Aliment Pharm Ther. 1995; 9: 547-553.
27. Fell JME, Paintin M, Arnoud-Battandier F, et al. Resolution of mucosal inflammation and fall in IL-1 beta mRNA in active Crohn's disease in response to polymeric diet. J Pediatr Gastro Nutr. 1997; 24: 474.
28. Modigliani R, Mary J, Simon J, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evaluation on prednisone. Gastroenterology. 1990; 98: 811-816.
29. Landi B, Anh T, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. Gastroenterology. 1992; 102: 1647-1653.
30. Rigaud D, Cosnes J, Quintrec Y, et al. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease. Gut. 1991; 32: 1492-1497.
31. Seidman E, Griffiths A, Jones A, et al. Semi-elemental diet versus prednisone in the treatment of acute Crohn's disease in children and adolescents. Gastroenterology. 1993; 104: A778.
32. Malchow H, Steinhardt HJ, Lorenz-Meyer H, et al. European Cooperative Crohn's Disease Study III. Scand J Gastroenterol. 1990; 25: 235-244.
33. Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study IV. Gastroenterology. 1991; 101: 881-888.
34. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's Disease. Gastroenterology. 2002; 122: 854-866.
35. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastro Nutr. 2000; 31: 8-15.
36. Griffiths AM. Enteral nutrition: the neglected primary therapy of active Crohn's disease. J Pediatr Gastro Nutr. 2000; 31: 3-5.
37. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000; 95: 3189-3194.
38. Zachos M, Tondeur M, Griffiths AM. A meta-analysis of enteral nutrition as primary therapy of active Crohn's disease: does formula composition influence efficacy? Cochrane Database Syst Rev. 2001; 3: 1-24.
39. Gassull MA, Fernandez-Banares F, Cabre E, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut. 2002; 51: 164-168.
40. Greenberg GR, Fleming CR, Jeejeebhoy KN, et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut. 1988; 29: 1309-1315.
41. Seidman E, Jones A, Issenman R, Griffiths AM. Cyclical exclusive enteral nutrition versus alternate day prednisone in maintaining remission of pediatric Crohn's disease. J Pediatr Gastro Nutr. 1996; 23: A344.
42. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997; 112: 1475-1481.
43. Colombel JF, Loftus EV Jr. Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31.
44. Dayharsh GA, Loftus EV Jr. Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002; 122: 72-77.